Adastra Holdings Announces Change of Auditor
Adastra Holdings Announces Change of Auditor
LANGLEY, BC / ACCESSWIRE / December 15, 2023 / Adastra Holdings Ltd. (CSE:XTRX)(FRA:D2EP) ("Adastra" or the "Company"), a leading cannabis processor and producer of the two top Canadian concentrates brands, with a focus on product innovation and commercialization for adult-use and medical markets, announces that it has changed its auditor from Davidson & Company LLP (the "Former Auditor") to MNP LLP (the "Successor Auditor"). The Company decided to change its auditor effective December 7, 2023 and the board of directors of the Company (the "Board") appointed the Successor Auditor on December 7, 2023, until the close of the next annual meeting of the shareholders of the Company or until its successor is appointed.
不列顛哥倫比亞省蘭利/ACCESSWIRE/2023年12月15日/Adastra Holdings Ltd.（CSE: XTRX）（FRA: D2EP）（“Adastra” 或 “公司”）是領先的大麻加工商，也是加拿大兩大濃縮物品牌的生產商，專注於成人用和醫療市場的產品創新和商業化，宣佈其核數師已從戴維森律師事務所（“前核數師”）改爲MNP LLP（“繼任核數師”）。公司決定更換核數師，自2023年12月7日起生效，公司董事會（“董事會”）於2023年12月7日任命了繼任核數師，直到公司下一次年度股東大會結束或其繼任者被任命爲止。
The Board and audit committee of the Company (the "Audit Committee") each approved the resignation of the Former Auditor and the appointment of the Successor Auditor in place of the Former Auditor. There were no reservations or modified opinions in the Former Auditor's audit reports for any financial period during which the Former Auditor was the Company's auditor and there are no "reportable events" (as defined in National Instrument 51-102 - Continuous Disclosure Obligations ("NI 51-102")) between the Company and the Former Auditor. The Notice of Change of Auditor was approved by the Board.
公司董事會和審計委員會（“審計委員會”）分別批准了前核數師的辭職和繼任核數師代替前核數師的任命。在前核數師擔任公司核數師的任何財政期間，前核數師的審計報告中沒有保留意見或修改意見，也沒有 “應報告的事件”（定義見國家儀器51-102- 持續披露義務 （“NI 51-102”）），該公司與前核數師之間。董事會批准了審計員變更通知。
In accordance with NI 51-102, the Notice of Change of Auditor, together with the required letters from the Former Auditor and the Successor Auditor, have been reviewed by the Audit Committee and Board and have been filed on SEDAR.
根據NI 51-102，核數師變更通知以及前核數師和繼任核數師的必要信函已由審計委員會和董事會審查，並已提交給SEDAR。
About Adastra Holdings Ltd.
關於阿達斯特拉控股有限公司
Adastra has become one of Canada's leaders in the supply and manufacturing of ethnobotanical and cannabis products for lawful adult-use. It serves medical markets and engages in forward-looking therapeutic applications. With cannabis concentrate products sold through retailers at more than 2,000 locations across Canada, Adastra's Phyto Extractions and Endgame Extracts brands are now well established with a solid distribution presence. As a Health Canada licensed facility, it specializes in extraction, distillation and manufacturing of a range of cannabis-derived products. Adastra partners with healthcare professionals and practitioners within the regulated environment to create products suitable for the medical cannabis market, with the ultimate aim of addressing the needs of patients. For more information, visit: .
Adastra已成爲加拿大供應和製造供成人合法使用的民族植物學和大麻產品的領導者之一。它服務於醫療市場並從事前瞻性治療應用。隨着加拿大2,000多個地點的零售商銷售大麻濃縮產品，Adastra的植物提取物和殘局提取物品牌現已建立牢固的分銷業務。作爲加拿大衛生部的許可機構，它專門從事一系列大麻衍生產品的提取、蒸餾和製造。Adastra與監管環境中的醫療保健專業人員和從業人員合作，開發適合醫用大麻市場的產品，最終目標是滿足患者的需求。欲了解更多信息，請訪問：。
Contacts
Michael Forbes, CEO, Corporate Secretary & Director
(778) 715-5011
michael@adastraholdings.ca
聯繫人
邁克爾·福布斯，首席執行官、公司秘書兼董事
(778) 715-5011
michael@adastraholdings.ca
SOURCE: Adastra Holdings Ltd.
來源：Adastra Holdings Ltd.
譯文內容由第三人軟體翻譯。